Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.01 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | reachable by antibody | 0.36 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 1 Parkinson's papers of 18 | 0.91 |
| pathways Reactome | in no curated pathway | 0.00 |
No case: the score is under the bar. Receipt 10503
Sealed predictions
- KRTCAP2 in dopamine neurons, braak-0.45 (p 0.224) → -0.45 (p 0.230)receipt 10511
Swarm cases
receipt 10511: KRTCAP2 in dopamine neurons, braak
- power
- full sample -0.44 (p 0.070, n 18), 95% CI -0.75 to +0.04. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.37 (p 0.132, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.28 (p 0.254, n 18). could be the mix.
- skeptic
- leave-one-out range -0.65 to -0.36, sign flips 0; without severely affected donors -0.44 (p 0.070, n 18). robust.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for KRTCAP2 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts